Sarepta and Roche halt DMD gene therapy’s use after second death
Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.
Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.
What's Your Reaction?
